Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study

Table 5 Correlation between objective (pH) and patient reported subjective outcomes in study patients PPI group on PPIs (6 months following high-dose PPI therapy)

Parameters	Regurgitation	RSI	GERD-HRQL	DMS	% total time	RE
Regurgitation	1.00
RSI	0.70 (<0.001)	1.00
GERD-HRQL	0.59 (0.005)	0.71 (<0.001)	1.00
DMS	−0.20 (0.399)	0.05 (0.838)	0.38 (0.107)	1.00
% total time	−0.12 (0.619)	0.12 (0.598)	0.41 (0.063)	0.94 (<0.001)	1.00
RE	0.10 (0.667)	0.31 (0.167)	0.46 (0.035)	0.77 (<0.001)	0.84 (<0.001)	1.00
Crossover patients off PPIs (6 months following transoral fundoplication)
Parameters	Regurgitation	RSI	GERD-HRQL	DMS	% total time	RE
Regurgitation	1.00
RSI	0.71 (<0.001)	1.00
GERD-HRQL	0.81 (<0.001)	0.62 (0.003)	1.00
DMS	0.18 (0.428)	0.14 (0.556)	0.04 (0.866)	1.00
% total time	0.11 (0.637)	0.09 (0.705)	0.08 (0.746)	0.89 (<0.001)	1.00
RE	0.17 (0.461)	0.14 (0.546)	0.14 (0.543)	0.65 (0.001)	0.80 (<0.001)	1.00
TF group off PPIs (12 months following transoral fundoplication)
Parameters	Regurgitation	RSI	GERD-HRQL	DMS	% total time	RE
Regurgitation	1.00
RSI	0.66 (<0.001)	1.00
GERD-HRQL	0.42 (0.010)	0.73 (<0.001)	1.00
DMS	0.02 (0.885)	0.10 (0.550)	0.35 (0.036)	1.00
% total time	0.06 (0.724)	0.10 (0.552)	0.39 (0.018)	0.98 (<0.001)	1.00
RE	0.21 (0.216)	0.13 (0.424)	0.41 (0.013)	0.83 (<0.001)	0.84 (<0.001)	1.00

Values are Spearman’s Rho (p values).
DMS, DeMeester score; GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPI, proton pump inhibitor; RE, reflux episodes; RSI, Reflux Symptom Index.
Regurgitation was assessed with Reflux Disease questionnaire. RSI was used to assess atypical symptoms. GERD-HRQL was used to assess typical symptoms.